Elite in Ovarian Carcinosarcoma

Dr. Alessandro D. Santin

Yale University
New Haven, CT
Elite
in Ovarian Carcinosarcoma
Specialties:Obstetrics and Gynecology | Oncology
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Alessandro Santin is an Obstetrics and Gynecologist and an Oncologist in New Haven, Connecticut. Dr. Santin and is rated as an Elite provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Ovarian Carcinosarcoma, Endometrial Cancer, Ovarian Cancer, Hysterectomy, and Salpingo-Oophorectomy.

His clinical research consists of co-authoring 225 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 11 articles in the study of Ovarian Carcinosarcoma.

Specialties
Obstetrics and Gynecology
Oncology
Licenses
Obstetrics & Gynecology in AR
Hospital Affiliations
Yale-New Haven Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna

Locations

YALE UNIVERSITY
20 York St, New Haven, CT 06510
203-688-4242
Other Locations
YALE UNIVERSITY
800 Howard Ave, New Haven, CT 06519
203-785-2140

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 24, 2025
Intervention Type: Biological
Study Phase: Phase 2
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 2
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and in Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and in Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drugs: VS-6766, Defactinib
Study Phase: Phase 2
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
Enrollment Status: Completed
Publish Date: January 16, 2025
Intervention Type: Drug
Study Drug: STRO-002
Study Phase: Phase 1
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: January 07, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO)
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO)
Enrollment Status: Completed
Publish Date: December 20, 2024
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 2
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drugs: Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan, Pemetrexed
Study Phase: Phase 3
Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3) Using a Novel Prime and Pull Strategy
Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3) Using a Novel Prime and Pull Strategy
Enrollment Status: Completed
Publish Date: May 02, 2024
Intervention Type: Drug
Study Drugs: 9-Valent HPV Vaccine, Imiquimod
Study Phase: Phase 2
Randomized Phase II Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in HER2/Neu+ Patients With Advance/Recurrent Uterine Serous Papillary Carcinoma
Randomized Phase II Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in HER2/Neu+ Patients With Advance/Recurrent Uterine Serous Papillary Carcinoma
Enrollment Status: Completed
Publish Date: May 17, 2023
Intervention Type: Drug
Study Drugs: Carboplatin/Paclitaxel, Trastuzumab
Study Phase: Phase 2
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 16, 2023
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
Enrollment Status: Completed
Publish Date: February 15, 2022
Intervention Type: Drug, Other
Study Drug: Copanlisib
Study Phase: Phase 2
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer
Enrollment Status: Completed
Publish Date: August 12, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 12 Less Clinical Trials

223 Total Publications

Unmet needs in cervical cancer - can biological therapies plug the gap?
Unmet needs in cervical cancer - can biological therapies plug the gap?
Journal: Expert opinion on biological therapy
Published: September 23, 2024
Similar Doctors
Expertise in
42
conditions
Dr. Elena S. Ratner
Obstetrics and Gynecology | Oncology
Expertise in
42
conditions
Dr. Elena S. Ratner
Obstetrics and Gynecology | Oncology

Yale University

1075 Chase Park Way, Suite B, 
Waterbury, CT 
 (18.0 mi)
203-755-6311
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Elena Ratner is an Obstetrics and Gynecologist and an Oncologist in Waterbury, Connecticut. Dr. Ratner and is rated as an Elite provider by MediFind in the treatment of Ovarian Carcinosarcoma. Her top areas of expertise are Ovarian Carcinosarcoma, Ovarian Cancer, Endometrial Cancer, Hysterectomy, and Salpingo-Oophorectomy.

Expertise in
30
conditions
Dr. Masoud Azodi
Gynecologic Oncology | Oncology
Expertise in
30
conditions
Dr. Masoud Azodi
Gynecologic Oncology | Oncology

Yale University

20 York St, 
New Haven, CT 
203-785-4638
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Masoud Azodi is a Gynecologic Oncologist and an Oncologist in New Haven, Connecticut. Dr. Azodi and is rated as an Elite provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Ovarian Carcinosarcoma, Ovarian Cancer, Endometrial Cancer, Hysterectomy, and Lymphadenectomy.

Expertise in
9
conditions
Dr. Gary H. Altwerger
Gynecologic Oncology | Obstetrics and Gynecology
Expertise in
9
conditions
Dr. Gary H. Altwerger
Gynecologic Oncology | Obstetrics and Gynecology

Yale University

20 York St, 
New Haven, CT 
203-785-4638
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gary Altwerger is a Gynecologic Oncologist and an Obstetrics and Gynecologist in New Haven, Connecticut. Dr. Altwerger and is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Ovarian Carcinosarcoma, Ovarian Cancer, Endometrial Cancer, Hormone Replacement Therapy (HRT), and Oophorectomy.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile